Search Results

You are looking at 1 - 10 of 87 items for :

  • "personalized medicine" x
  • Refine by Access: All x
Clear All
Full access

Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook

clinical practice. 1 – 5 A challenge to the adoption of personalized medicine biomarkers in oncology is the lack of a standardized validation process because of the heterogeneity of tumor types, treatments, and tests themselves. 1 , 3 , 6 – 8 Validation

Full access

James O. Armitage, William C. Wood, and Dan L. Longo

not likely to be effective without a trusting and respectful relationship already in place. This is the sort of “personalized medicine” that effective physicians have been practicing since before the term became part of our medical vernacular

Full access

Harold J. Burstein

Full access

Gregory P. Kalemkerian

participated in relevant clinical trials over the past decade. Being enticed by the marvels of molecular technology and the promise of personalized medicine is easy, particularly when confronted by the limitations of current therapy. I recently received an e

Full access

Giuseppe Curigliano

which she lives. Across borders and cultures, breast cancer experience is emotionally distressing. Oncologists should help our patients to overcome their difficulties through personalized communication, no less than personalized medicine, using the

Full access

Julian C. Schink and Larry J. Copeland

goal of personalized medicine. In his 2009 ASCO Presidential Address, Richard Schilsky commented, As cancer specialists, we have long recognized that each patient is unique.... We now recognize that, just as each patient is different in how he or she

Full access

Wing C. Chan and James O. Armitage

agents specific for different oncogenic pathways, non-Hodgkin’s lymphoma may conceivably be treated in the future with drugs directed against selected pathways that are active in individual tumors ( Figure 1 ). The era of personalized medicine for

Full access

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

R apidly evolving genetic and genomic technologies for genetic cancer risk assessment (GCRA) are revolutionizing the approach to targeted therapy and cancer screening and prevention, heralding the era of personalized medicine. Although academic

Full access

Alan P. Venook, Maria E. Arcila, Al B. Benson III, Donald A. Berry, David Ross Camidge, Robert W. Carlson, Toni K. Choueiri, Valerie Guild, Gregory P. Kalemkerian, Razelle Kurzrock, Christine M. Lovly, Amy E. McKee, Robert J. Morgan, Anthony J. Olszanski, Mary W. Redman, Vered Stearns, Joan McClure, and Marian L. Birkeland

participation, 26; too early, 44. b Regional therapy, 8; ineligible for participation, 10; too early, 2. From Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

Full access

David M. Thomas and Andrew J. Wagner

dramatic response to a drug is not yet known. In an age of personalized medicine, biomarkers predictive of response (or nonresponse) will be critical to optimize outcomes and direct the appropriate use of high-cost therapeutic agents. EDITOR